Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncolytic Measles Virotherapy and Opposition to Measles Vaccination.
Russell SJ, Babovic-Vuksanovic D, Bexon A, Cattaneo R, Dingli D, Dispenzieri A, Deyle DR, Federspiel MJ, Fielding A, Galanis E, Lacy MQ, Leibovich BC, Liu MC, Muñoz-Alía M, Miest TC, Molina JR, Mueller S, Okuno SH, Packiriswamy N, Peikert T, Raffel C, Van Rhee F, Ungerechts G, Young PR, Zhou Y, Peng KW. Russell SJ, et al. Among authors: bexon a. Mayo Clin Proc. 2019 Sep;94(9):1834-1839. doi: 10.1016/j.mayocp.2019.05.006. Epub 2019 Jun 22. Mayo Clin Proc. 2019. PMID: 31235278 Free PMC article. Review.
IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers.
Vandergaast R, Carey T, Reiter S, Lathrum C, Lech P, Gnanadurai C, Haselton M, Buehler J, Narjari R, Schnebeck L, Roesler A, Sevola K, Suksanpaisan L, Bexon A, Naik S, Brunton B, Weaver SC, Rafael G, Tran S, Baum A, Kyratsous CA, Peng KW, Russell SJ. Vandergaast R, et al. Among authors: bexon a. mSphere. 2021 Jun 30;6(3):e0017021. doi: 10.1128/mSphere.00170-21. Epub 2021 Jun 2. mSphere. 2021. PMID: 34077262 Free PMC article.
Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2.
Vandergaast R, Carey T, Reiter S, Lech P, Gnanadurai C, Tesfay M, Buehler J, Suksanpaisan L, Naik S, Brunton B, Recker J, Haselton M, Ziegler C, Roesler A, Mills JR, Theel E, Weaver SC, Rafael G, Roforth MM, Jerde C, Tran S, Diaz RM, Bexon A, Baum A, Kyratsous CA, Peng KW, Russell SJ. Vandergaast R, et al. Among authors: bexon a. bioRxiv [Preprint]. 2020 May 27:2020.05.26.117549. doi: 10.1101/2020.05.26.117549. bioRxiv. 2020. PMID: 32577655 Free PMC article. Updated. Preprint.
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.
Cottu PH, Bonneterre J, Varga A, Campone M, Leary A, Floquet A, Berton-Rigaud D, Sablin MP, Lesoin A, Rezai K, Lokiec FM, Lhomme C, Bosq J, Bexon AS, Gilles EM, Proniuk S, Dieras V, Jackson DM, Zukiwski A, Italiano A. Cottu PH, et al. Among authors: bexon as. PLoS One. 2018 Oct 10;13(10):e0204973. doi: 10.1371/journal.pone.0204973. eCollection 2018. PLoS One. 2018. PMID: 30304013 Free PMC article. Clinical Trial.
Stereotactic Radiosurgery for Poor Performance Status Patients.
Kubicek GJ, Turtz A, Xue J, Patel A, Richards G, LaCouture T, Cappelli L, Diestelkamp T, Saraiya P, Bexon A, Lerman N, Goldman HW. Kubicek GJ, et al. Among authors: bexon a. Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):956-959. doi: 10.1016/j.ijrobp.2016.02.041. Epub 2016 Feb 16. Int J Radiat Oncol Biol Phys. 2016. PMID: 27113565
A single-dose PK study of onapristone including the effect of food on absorption.
Rezai K, Chassard D, Denot C, Proniuk S, Zukiwski A, Gilles E, Ramos HL, Patat A, Bexon A, Lokiec F. Rezai K, et al. Among authors: bexon a. Cancer Chemother Pharmacol. 2015 Jul;76(1):171-7. doi: 10.1007/s00280-015-2754-3. Epub 2015 May 26. Cancer Chemother Pharmacol. 2015. PMID: 26006702 Clinical Trial.
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Ruzsa A, Sen M, Evans M, Lee LW, Hideghety K, Rottey S, Klimak P, Holeckova P, Fayette J, Csoszi T, Erfan J, Forssmann U, Goddemeier T, Bexon A, Nutting C; NA EMD 1201081 Study Group. Ruzsa A, et al. Among authors: bexon a. Invest New Drugs. 2014 Dec;32(6):1278-84. doi: 10.1007/s10637-014-0117-2. Epub 2014 Jun 4. Invest New Drugs. 2014. PMID: 24894651 Clinical Trial.
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Smith DA, Conkling P, Richards DA, Nemunaitis JJ, Boyd TE, Mita AC, de La Bourdonnaye G, Wages D, Bexon AS. Smith DA, et al. Among authors: bexon as. Cancer Immunol Immunother. 2014 Aug;63(8):787-96. doi: 10.1007/s00262-014-1547-6. Epub 2014 Apr 27. Cancer Immunol Immunother. 2014. PMID: 24770667 Free PMC article. Clinical Trial.
18 results